{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:38:33Z","timestamp":1719952713833},"reference-count":43,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.ejphar.2014.01.069","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T17:30:28Z","timestamp":1392139828000},"page":"135-140","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Atorvastatin prevents type 2 diabetes mellitus\u2014An experimental study"],"prefix":"10.1016","volume":"728","author":[{"given":"Sri Venkata","family":"Madhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Galav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapan Kumar","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiman Abbas","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.01.069_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(02)01547-9","article-title":"Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipaemia","volume":"444","author":"Aoki","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.069_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0021-9150(98)00198-1","article-title":"Metabolic modes of action of the statins in the hyperlipoproteinemias","volume":"141","author":"Aguilar-Salinas","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2014.01.069_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.069_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1194\/jlr.M300309-JLR200","article-title":"Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia","volume":"45","author":"Bilz","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.01.069_bib5","doi-asserted-by":"crossref","first-page":"E1269","DOI":"10.1152\/ajpendo.90207.2008","article-title":"Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague Dawley rats","volume":"295","author":"Cacho","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2014.01.069_bib6","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00007890-200210270-00001","article-title":"Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets","volume":"74","author":"Contreras","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ejphar.2014.01.069_bib8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/dc12-1756","article-title":"Statins and risk of diabetes:an analysis of electronic medical records to evaluate possible bias due to differential survival","volume":"36","author":"Danaei","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.069_bib9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2014.01.069_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.metabol.2009.08.011","article-title":"Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice","volume":"59","author":"Furuya","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2014.01.069_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/meta.2003.50097","article-title":"Experimental model of post prandial hypertriglyceridemia in sucrose fed rats and the effectiveness of atorvastatin in the model","volume":"52","author":"Fanatsu","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2014.01.069_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.01.069_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.biopha.2004.09.005","article-title":"Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome","volume":"58","author":"Guclu","year":"2004","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejphar.2014.01.069_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbrc.2008.05.095","article-title":"A novel membrane-based anti-diabetic action of atorvastatin","volume":"372","author":"Horvath","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2014.01.069_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjcard.2006.01.055","article-title":"Effect of atorvastatin (10mg\/day) on glucose metabolism in patients with the metabolic syndrome","volume":"98","author":"Huptas","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.069_bib16","doi-asserted-by":"crossref","first-page":"1611S","DOI":"10.1093\/ajcn\/65.5.1611S","article-title":"n-3 Fatty acids and serum lipoproteins: animal studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2014.01.069_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2014.01.069_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"Koh","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.069_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.01.069_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabres.2005.02.005","article-title":"Cameroon local diet-induced glucose intolerance and dyslipaemia in adult Wistar rat","volume":"69","author":"Kamgang","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2014.01.069_bib21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1248\/bpb.26.1681","article-title":"Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin","volume":"26","author":"Kanda","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2014.01.069_bib22","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.069_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0021-9150(95)05576-I","article-title":"Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models","volume":"117","author":"Krause","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2014.01.069_bib24","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1152\/ajpendo.00132.2010","article-title":"Effects of atorvastatin on the regeneration of pancreatic \u03b2-cells after streptozotocin treatment in the neonatal rodent","volume":"299","author":"Marchand","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2014.01.069_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/diabetes.48.6.1258","article-title":"Triglyceride-induced diabetes associated with familial lipoprotein lapase deficiency","volume":"48","author":"Mingrone","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.01.069_bib26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control","volume":"49","author":"Nakata","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2014.01.069_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/meta.2002.32726","article-title":"Chronic feeding of nitric oxide synthase inhibitor induces postprandial hypertriglyceridemia in type 2 diabetic model rats, OLETF rats, but not in nondiabetic rats","volume":"51","author":"Nakaya","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2014.01.069_bib28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0706917","article-title":"Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study","volume":"149","author":"Pierno","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.069_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Peter","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefit and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib31","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.01.069_bib32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin","volume":"353","author":"Rosensen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib34","first-page":"151","article-title":"Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients","volume":"22","author":"Sonmez","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2014.01.069_bib35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.01.069_bib36","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.01.069_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0026-0495(95)90115-9","article-title":"Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in non-diabetic subjects with mild hypertriglyceridemia","volume":"44","author":"Sane","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2014.01.069_bib38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2337\/diacare.16.11.1494","article-title":"Does familial hypertriglyceridemia predispose to NIDDM?","volume":"16","author":"Sane","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.069_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/39335","article-title":"Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function","volume":"389","author":"Uysal","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2014.01.069_bib40","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"S16","key":"10.1016\/j.ejphar.2014.01.069_bib41","first-page":"412","article-title":"Low dose streptozotocin (STZ) combined with high energy intake can effectively induce type 2 diabetes through altering the related gene expression","author":"Wang","year":"2007","journal-title":"Asia Pacif. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2014.01.069_bib42","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of l-type Ca2+ channels in rat islet beta-cells","volume":"126","author":"Yada","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.069_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/aps.2009.176","article-title":"Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate","volume":"31","author":"Zhang","year":"2010","journal-title":"Acta Pharmacol. Sin."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T10:46:26Z","timestamp":1565174786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":43,"alternative-id":["S0014299914001149"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.069","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atorvastatin prevents type 2 diabetes mellitus\u2014An experimental study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}